drugset / Trial / NCT06638502

Safety of HRX215 in Patients After Minor and Major Liver Resection

NCT06638502 ↗

Phase 1/2 Recruiting 80 enrolled HepaRegeniX GmbH
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this clinical trial is to learn if HRX215 is safe, tolerable and active in adults who have undergone liver resection due to colorectal carcinoma metastases. The objectives are: 1. to learn about the safety and tolerability of HRX215 2. to learn about how the body absorbs, distributes, and gets rid of HRX215. 3. to learn about clinical activity of HRX215 Researchers will compare HRX215 to a placebo (a look-alike substance that contains no drug) to investigate safety, tolerability and clinical activity in participants taking HRX215.

Timeline

Start
2025-05-06
Primary completion
2027-07-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject HRX215 Unknown 250 mg Oral